Delcath Systems Inc (DCTH)vsStryker Corporation (SYK)
DCTH
Delcath Systems Inc
$13.01
-3.77%
HEALTHCARE · Cap: $446.71M
SYK
Stryker Corporation
$329.78
+0.82%
HEALTHCARE · Cap: $125.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 27841% more annual revenue ($25.27B vs $90.44M). SYK leads profitability with a 13.2% profit margin vs 0.6%. SYK appears more attractively valued with a PEG of 1.56. SYK earns a higher WallStSmart Score of 55/100 (C-).
DCTH
Hold35
out of 100
Grade: F
SYK
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCTH.
Margin of Safety
-47.5%
Fair Value
$223.53
Current Price
$329.78
$106.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 26.3% year-over-year
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of 0.5% — below average capital efficiency
0.6% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 1294.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Bear Case : SYK
The primary concerns for SYK are PEG Ratio, P/E Ratio, Revenue Growth.
Key Dynamics to Monitor
DCTH profiles as a growth stock while SYK is a value play — different risk/reward profiles.
SYK carries more volatility with a beta of 0.78 — expect wider price swings.
DCTH is growing revenue faster at 26.3% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (55/100 vs 35/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?